In Union of India versus Cipla Limited, the Supreme Court of India upheld central government notifications fixing drug price norms under the Drugs (Prices Control) Order, 1995. Justices Madan B. Lokur and R.K. Agrawal ruled that statutory price fixation constitutes a legislative function subject to narrow judicial review.
Statutory Framework of the Drugs (Prices Control) Order, 1995
The Drugs (Prices Control) Order, 1995 (DPCO 1995) was promulgated by the Central Government pursuant to Section 3 of the Essential Commodities Act, 1955. Its statutory objective is to ensure the availability of essential medicines and bulk drugs at fair and reasonable prices across India. The order establishes a structured regulatory scheme governing both bulk drug prices (Paragraph 3) and retail price ceilings for scheduled formulations (Paragraphs 7, 8, and 9).
Under Paragraph 7 of DPCO 1995, the Central Government is empowered to establish general or specific norms for conversion costs (CC), packing charges (PC), and process losses (PL) of raw materials and packaging materials. These norms serve as standardized inputs for calculating maximum retail prices under the statutory formula: Retail Price = (Material Cost + Conversion Cost + Packing Material Cost + Packing Charges) × (1 + Maximum Allowable Post-manufacturing Expenses / 100) + Excise Duty.
The Challenge by Pharmaceutical Manufacturers
In 1999, the Central Government issued notifications prescribing revised norms for conversion costs, packing charges, and process losses. Leading pharmaceutical manufacturers, including Cipla Limited, Martin & Harris Laboratories, and Dr. Reddy's Laboratories, challenged these notifications before several High Courts, particularly the Allahabad High Court and Karnataka High Court.
The manufacturers contended that the notifications were issued mechanically without proper application of mind, without collecting fresh cost data, and without conducting annual normative revisions as contemplated under DPCO 1995. They further argued that fixing the retail price of scheduled formulations under Paragraph 8 was invalid unless the government had first determined and notified the sale price of the constituent bulk drug under Paragraph 3.
The Allahabad High Court had accepted these challenges and struck down several price-fixing notifications. The Union of India appealed these rulings to the Supreme Court.
Operating within heavily regulated industries demands strict adherence to the statutory regulatory compliance framework established by regulatory bodies.
Supreme Court Ruling on Norm Fixation and Industry Non-Cooperation
The Supreme Court bench comprising Justice Madan B. Lokur and Justice R.K. Agrawal set aside the judgments of the High Courts and allowed the appeals filed by the Union of India. The bench examined the detailed factual history of how expert committees, including the Bureau of Industrial Costs and Prices (BICP), conducted costing studies.
The Supreme Court observed that the government had made multiple requests to pharmaceutical manufacturers and industry associations to furnish verifiable cost data, accounting sheets, and production records. The industry repeatedly failed to provide the necessary cooperation or submitted incomplete information. The court held that manufacturers who withhold operational cost data cannot subsequently challenge the government's normative calculations for lacking granular cost verification.
The court held that Paragraph 7 does not mandate an exhaustive plant-by-plant inquiry for every individual manufacturer. Instead, the Central Government possesses the discretion to establish broad industry-wide norms based on representative studies to advance the public interest in affordable healthcare.
This principle of assessing institutional conduct mirrors evidentiary requirements in judicial adjudications where parties cannot benefit from their own failure to produce available evidence.
Independent Pricing of Formulations under Paragraphs 8 and 9
The Supreme Court also resolved the statutory interpretation issue regarding Paragraph 8 versus Paragraph 3 of DPCO 1995. The court held that the power to fix the retail price of a formulation under Paragraph 8 is not conditioned on the prior fixation of a bulk drug price under Paragraph 3. Where a bulk drug price has not been fixed, the actual landed purchase cost of the bulk drug is utilized in the retail price formula, ensuring that price control mechanisms remain fully operational.
Scope of Judicial Review in Economic and Pricing Decisions
A central holding of the judgment concerns the constitutional limits of judicial review in price-fixing matters:
- Price Fixation is Legislative in Character: The fixation of prices under delegated statutory authority is in the nature of legislative activity rather than a quasi-judicial inquiry.
- Narrow Grounds of Interference: Courts will not sit as appellate bodies over economic formulas or expert accounting determinations. Judicial review is confined to examining whether the authority acted ultra vires the parent statute, violated fundamental rights, or acted with patent arbitrariness.
- Public Interest Predominance: The statutory mandate of the Essential Commodities Act to ensure affordable life-saving medicines takes precedence over individual commercial convenience.